Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery

Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A

(2014) Andrea E. Prota et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Tivantinib: critical review with a focus on hepatocellular carcinoma

(2014) Elena Rota Caremoli et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids

(2014) Seneha Santoshi et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization

(2014) Andrea E. Prota et al.   JOURNAL OF MOLECULAR BIOLOGY

Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter-Mediated Drug Resistance

(2014) A. Aoyama et al.   MOLECULAR CANCER THERAPEUTICS

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

(2014) A. E. Prota et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

(2013) Yoon-Koo Kang et al.   INVESTIGATIONAL NEW DRUGS

Towards the identification of the binding site of benzimidazoles to β-tubulin of Trichinella spiralis: Insights from computational and experimental data

(2013) Rodrigo Aguayo-Ortiz et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents

(2013) A. E. Prota et al.   SCIENCE

Determination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapy

(2013) Siamak Ravanbakhsh et al.   Theoretical Biology and Medical Modelling

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

(2012) Jonathan W. Goldman et al.   CANCER

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

(2012) Matthew Burge et al.   INVESTIGATIONAL NEW DRUGS

An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

(2012) Yan Lu et al.   PHARMACEUTICAL RESEARCH

Multi-Target Drugs: The Trend of Drug Research and Development

(2012) Jin-Jian Lu et al.   PLoS One

Nocodazole is a High-Affinity Ligand for the Cancer-Related Kinases ABL, c-KIT, BRAF, and MEK

(2011) Hwangseo Park et al.   ChemMedChem

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

(2011) Michael Millward et al.   INVESTIGATIONAL NEW DRUGS

Anti-microtubule ‘plinabulin’ chemical probe KPU-244-B3 labeled both α- and β-tubulin

(2010) Yuri Yamazaki et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

(2010) J D Lickliter et al.   BRITISH JOURNAL OF CANCER

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

(2010) M. M. Mita et al.   CLINICAL CANCER RESEARCH

Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers

(2010) Pascale Barbier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MolProbity: all-atom structure validation for macromolecular crystallography

(2009) Vincent B. Chen et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Discovery of CYT997: a structurally novel orally active microtubule targeting agent

(2009) Christopher J. Burns et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Variations in the colchicine-binding domain provide insight into the structural switch of tubulin

(2009) A. Dorleans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb  -Tubulin in Vinca Alkaloid Sensitivity

(2008) P. P. Gan et al.   CANCER RESEARCH

Tubulin modifications and their cellular functions

(2008) Jennetta W Hammond et al.   CURRENT OPINION IN CELL BIOLOGY